Reimar Wernich Thomsen

Reimar Wernich Thomsen

Auto-generated profile, based on publicly available information

Reimar Wernich Thomsen

Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2015 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
ESElisabeth Svensson
Elisabeth Svensson
EHErzsébet Horváth‐Puhó
Erzsébet Horváth‐Puhó
RTReimar W. Thomsen
Reimar W. Thomsen
JDJens Christian Djurhuus
Jens Christian Djurhuus
LPLars Pedersen
Lars Pedersen
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen

1 November 2013 in Clinical Epidemiology
Verified
Journal Article
Open access
MSMette Søgaard
Mette Søgaard
RTReimar Wernich Thomsen
Reimar Wernich Thomsen
KBKristine Skovgaard Bossen
Kristine Skovgaard Bossen
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
MNMette Nørgaard
Mette Nørgaard
Peer reviewed article authored by (Søgaard M, Thomsen RW, Bossen KS, Sørensen HT, Nørgaard M). Read article or submit your manuscript for publishing.

14 July 2011 in BMC Public Health
Verified
Journal Article
Open access
PDF file
VHVictoria Hall
Victoria Hall
RTReimar W Thomsen
Reimar W Thomsen
OHOle Henriksen
Ole Henriksen
NLNicolai Lohse
Nicolai Lohse
Diabetes prevalence is increasing globally, and Sub-Saharan Africa is no exception. With diverse health challenges, health authorities in Sub-Saharan Africa and international donors need robust data on the epidemiology and impact of diabetes in order to plan and prioritise their health programmes. This paper aims to provide a comprehensive and up-to-date review of the epidemiological trends and public health implications of diabetes in Sub-Saharan Africa.

10 July 2012 in Thorax
Verified
Journal Article
Open access
PDF file
CAClaire Andréjak
Claire Andréjak
RNRikke Nielsen
Rikke Nielsen
VTVibeke Ø Thomsen
Vibeke Ø Thomsen
PDPierre Duhaut
Pierre Duhaut
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
RTReimar Wernich Thomsen
Reimar Wernich Thomsen
Background Chronic respiratory disease and inhaled corticosteroid (ICS) therapy for chronic obstructive pulmonary disease (COPD) increase the risk of pneumonia. Few data are available on the association of these risk factors with non-tuberculous mycobacterial (NTM) pulmonary disease. Methods This study examined chronic respiratory diseases and ICS use as risk factors in a population-based case-control study encompassing all adults in Denmark with microbiologically confirmed NTM pulmonary disease between 1997 and 2008. The study included 10 matched population controls per case. Conditional logistic regression was used to compute adjusted ORs for NTM pulmonary disease with regard to chronic respiratory disease history. Results Overall, chronic respiratory disease was associated with a 16.5-fold (95% CI 12.2 to 22.2) increased risk of NTM pulmonary disease. The adjusted OR for NTM disease was 15.7 (95% CI 11.4 to 21.5) for COPD, 7.8 (95% CI 5.2 to 11.6) for asthma, 9.8 (95% CI 2.03 to 52.8) for pneumoconiosis, 187.5 (95% CI 24.8 to 1417.4) for bronchiectasis, and 178.3 (95% CI 55.4 to 574.3) for tuberculosis history. ORs were 29.1 (95% CI 13.3 to 63.8) for patients with COPD on current ICS therapy and 7.6 (95% CI 3.4 to 16.8) for patients with COPD who had never received ICS therapy. Among patients with COPD, ORs increased according to ICS dose, from 28.1 for low-dose intake to 47.5 for high-dose intake (more than 800 μg/day). The OR was higher for fluticasone than for budesonide. Conclusion Chronic respiratory disease, particularly COPD treated with ICS therapy, is a strong risk factor for NTM pulmonary disease.

1 August 2008 in Diabetes Care
Verified
Journal Article
Open access
JKJette B. Kornum
Jette B. Kornum
RTReimar W. Thomsen
Reimar W. Thomsen
ARAnders Riis
Anders Riis
HLHans-Henrik Lervang
Hans-Henrik Lervang
HSHenrik C. Schønheyder
Henrik C. Schønheyder
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
OBJECTIVE—To examine whether diabetes is a risk factor for hospitalization with pneumonia and to assess the impact of A1C level on such risk. RESEARCH DESIGN AND METHODS—In this population-based, case-control study we identified patients with a first-time pneumonia-related hospitalization between 1997 and 2005, using health care databases in northern Denmark. For each case, 10 sex- and age-matched population control subjects were selected from Denmark's Civil Registration System. We used conditional logistic regression to compute relative risk (RR) for pneumonia-related hospitalization among subjects with and without diabetes, controlling for potential confounding factors. RESULTS—The study included 34,239 patients with a pneumonia-related hospitalization and 342,390 population control subjects. The adjusted RR for pneumonia-related hospitalization among subjects with diabetes was 1.26 (95% CI 1.21–1.31) compared with nondiabetic individuals. The adjusted RR was 4.43 (3.40–5.77) for subjects with type 1 diabetes and 1.23 (1.19–1.28) for subjects with type 2 diabetes. Diabetes duration ≥10 years increased the risk of a pneumonia-related hospitalization (1.37 [1.28–1.47]). Compared with subjects without diabetes, the adjusted RR was 1.22 (1.14–1.30) for diabetic subjects whose A1C level was <7% and 1.60 (1.44–1.76) for diabetic subjects whose A1C level was ≥9%. CONCLUSIONS—Type 1 and type 2 diabetes are risk factors for a pneumonia-related hospitalization. Poor long-term glycemic control among patients with diabetes clearly increases the risk of hospitalization with pneumonia.

26 May 2009 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
Zitta F B Barrella HarboeZitta F B Barrella Harboe
Zitta F B Barrella Harboe
RTReimar W Thomsen
Reimar W Thomsen
ARAnders Riis
Anders Riis
PVPalle Valentiner-Branth
Palle Valentiner-Branth
JCJens Jørgen Christensen
Jens Jørgen Christensen
TBThomas Benfield
Thomas Benfield
Pneumococcal disease is a leading cause of morbidity and mortality worldwide. The aim of this study was to investigate the association between specific pneumococcal serotypes and mortality from invasive pneumococcal disease (IPD). In a nationwide population-based cohort study of IPD in Denmark during 1977–2007, 30-d mortality associated with pneumococcal serotypes was examined by multivariate logistic regression analysis after controlling for potential confounders. A total of 18,858 IPD patients were included. Overall 30-d mortality was 18%, and 3% in children younger than age 5 y. Age, male sex, meningitis, high comorbidity level, alcoholism, and early decade of diagnosis were significantly associated with mortality. Among individuals aged 5 y and older, serotypes 31, 11A, 35F, 17F, 3, 16F, 19F, 15B, and 10A were associated with highly increased mortality as compared with serotype 1 (all: adjusted odds ratio ≥3, p<0.001). In children younger than 5 y, associations between serotypes and mortality were different than in adults but statistical precision was limited because of low overall childhood-related mortality. Specific pneumococcal serotypes strongly and independently affect IPD associated mortality.